Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...

Abzena and Mabqi bring together two organizations that are focused on advancing antibody innovation through integration.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Researchers analyzed the role of NUDT5 and its interaction with other proteins in the folate pathway and in regulating purine synthesis.